Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marit J van Gils

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
Expert Review of Vaccines|June 9, 2020
Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domainsNina M C De Jong, Aafke Aartse, Marit J Van Gils, et al.
The Journal of General Virology|October 2, 2009
High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activityMarit J van Gils, Diana Edo-Matas, Becky Schweighardt, et al.
Current HIV Research|July 3, 2025
Innovative Single-Cell Sequencing Techniques for B-Cell Analysis and Their Implications for Rational HIV-1 Vaccine DesignDenise Guerra, Laura T M Graus, Tim Beaumont, et al.
Human Vaccines & Immunotherapeutics|September 21, 2016
Natural infection as a blueprint for rational HIV vaccine designMarlies M van Haaren, Tom L G M van den Kerkhof, Marit J van Gils
Plos One|February 2, 2013
Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individualsZelda Euler, Marit J van Gils, Brigitte D Boeser-Nunnink, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 8, 2020
[HIV vaccine: how far along are we?]Emma I M M Reiss, Marit J van Gils, Rogier W Sanders, et al.
Frontiers in Medical Technology|April 14, 2022
Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and ImplementationKarlijn van der Straten, Marit J van Gils, Steven W de Taeye, et al.
The Journal of Infectious Diseases|February 23, 2010
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progressionZelda Euler, Marit J van Gils, Evelien M Bunnik, et al.
Antiviral Research|September 29, 2024
Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functionsAngela I Schriek, David Falck, Manfred Wuhrer, et al.
Journal of Human Lactation : Official Journal of International Lactation Consultant Association|June 21, 2022
Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-MatchSien J Mulleners, Hannah G Juncker, Marit J van Gils, et al.
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
Expert Review of Vaccines|June 9, 2020
Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domainsNina M C De Jong, Aafke Aartse, Marit J Van Gils, et al.
The Journal of General Virology|October 2, 2009
High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activityMarit J van Gils, Diana Edo-Matas, Becky Schweighardt, et al.
Current HIV Research|July 3, 2025
Innovative Single-Cell Sequencing Techniques for B-Cell Analysis and Their Implications for Rational HIV-1 Vaccine DesignDenise Guerra, Laura T M Graus, Tim Beaumont, et al.
Human Vaccines & Immunotherapeutics|September 21, 2016
Natural infection as a blueprint for rational HIV vaccine designMarlies M van Haaren, Tom L G M van den Kerkhof, Marit J van Gils
Plos One|February 2, 2013
Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individualsZelda Euler, Marit J van Gils, Brigitte D Boeser-Nunnink, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 8, 2020
[HIV vaccine: how far along are we?]Emma I M M Reiss, Marit J van Gils, Rogier W Sanders, et al.
Frontiers in Medical Technology|April 14, 2022
Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and ImplementationKarlijn van der Straten, Marit J van Gils, Steven W de Taeye, et al.
The Journal of Infectious Diseases|February 23, 2010
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progressionZelda Euler, Marit J van Gils, Evelien M Bunnik, et al.
Antiviral Research|September 29, 2024
Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functionsAngela I Schriek, David Falck, Manfred Wuhrer, et al.
Journal of Human Lactation : Official Journal of International Lactation Consultant Association|June 21, 2022
Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-MatchSien J Mulleners, Hannah G Juncker, Marit J van Gils, et al.
Pageof 23